The pharmaceutical company Bayer billed 787 million euros in 2025 in Spain. The figure represents a drop of 4% compared to the previous year, in which the firm achieved sales of 822 million. As explained by the CEO of the Bayer subsidiary in Spain, Jordi Sánchez, the drop in billing is mainly due to the withdrawal from the market of the insecticide Movento, which has been banned in Europe. This impact has been particularly noticeable in the sales of the company's agricultural division –the Crop Science area–, which has reduced sales by 20%, to 227 million euros.